

PD Theranostics, Inc., a Lucius Partners Company, Announces Key License Agreement and Provides Corporate Update

Licensing Key IP from the Massachusetts General Hospital to create improved clinical decision-making tools

NEW YORK, NEW YORK, USA, April 6, 2022 /EINPresswire.com/ -- PD Theranostics, Inc., a Lucius Partners Company, Announces Key License Agreement and Provides Corporate Update



The Company is excited to finalize its license for this unique intellectual property. The patent will allow to PDTx to further enhance the value of the data they generate and expand business."

PDTx board of directors member and Lucius Partners founder James Ahern

Licensing Key IP from the Massachusetts General Hospital to create improved clinical decision-making tools. Utilizing proprietary workflows and algorithms to begin generating the data required to advance the platform technology.

Lucius Partners, LLC today announced that its portfolio company, PD Theranostics, Inc. (PDTx), announced a corporate update and reviewed recent progress developing its theranostic platform to address unmet medical needs in

important patient populations.

First, the company reported that it has signed an agreement with the Massachusetts General Hospital (MGH) to secure foundational intellectual property to further develop the Company's theranostic platform.

Additionally, PDTx is actively using analysis of prostate tissue samples to finalize the initial optimization and standardization of its proprietary prognostic imaging workflows and Artificial Intelligence (AI) algorithms. The AI is designed to enhance interpretation of existing pathology results and provide novel predictive data to anchor and improve clinical decision-making. The unique, patient specific

information, which may allow healthcare providers to better tailor treatments for their patients, is currently unavailable in clinical practice.

Dr. Mark Poznansky, scientific co-founder of PDTx stated, "Providing novel, clinical decision-enabling data with the highest utility to pathologists and clinicians drives our research efforts. This intellectual property will support the efforts of PDTx to accelerate and expand its science and tools to help patients receive the most appropriate treatments. While our initial focus is on creating predictive artificial intelligence (AI) solutions in solid tumors and infections, we believe this technology has the potential to have a transformative impact on patient care in many medical conditions." Dr. Poznansky is also Director of the Vaccine and Immunotherapy Center at MGH, and Professor of Medicine at Harvard Medical School.

"PDTx continues to improve and scale our proprietary imaging AI platform by generating initial data based on prostate tissue samples. This data will advance our identification of cellular signatures and prognostic biomarkers that could indicate various disease risks and treatments," said Patrick Gallagher, Chief Executive Officer of PD Theranostics, Inc. "Licensing this foundational patent from MGH will allow us to further explore the potential for AI to maximize clinical predictiveness while optimizing system flexibility to address tissue samples across multiple disease states. Generating actionable data that is derived at the cellular level has the potential, we believe, to be a significant step toward improved patient outcomes."

"The Company is excited to finalize its license for this unique intellectual property," said PDTx board of directors member and Lucius Partners founder James Ahern. "The patent will allow to PDTx to further enhance the value of the data they generate and expand business opportunities. We believe that our intellectual property strategy will drive the development of a broad portfolio of computational

pathology applications and create shareholder value.”

About PD Theranostics, Inc.

PD Theranostics is developing AI guided algorithms while leveraging proprietary workflows and methods

utilizing imaging-based methodologies to diagnose and guide clinical decision making around specific

targeted therapies and their efficacy in human disease states, including cancer, infectious diseases and

complications of diabetes including diabetic foot ulcers. Please visit www.pdtheranostics.com for more information.

About Lucius Partners, LLC

Lucius Partners is a consultancy that provides a broad suite of services to help healthcare companies

grow, achieve milestones and generate value for their shareholders.

Lucius Partners, LLC

12 E. 49th St., 11th Floor, New York, NY 10017

Contact:

Patrick Gallagher, CEO

PD Theranostics, Inc.

pgallagher@luciuspartnersllc.com

Matthew Duffy, President

PD Theranostics, Inc.

mduffy@luciuspartnersllc.co

Matthew Duffy

PD Theranostics, Inc.

pgallagher@luciuspartnersllc.com

This press release can be viewed online at: <https://www.einpresswire.com/article/567705927>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2022 IPD Group, Inc. All Right Reserved.